Articles cited in the review are from the Pubmed database from the years 2016–2025 (excluding articles that describe the first use of a given drug), selected based on the following keywords: drugs targeting PI3K/AKT/mTOR pathway breast cancer, TNBC therapy, nanoparticles in breast cancer. This evidence concerns the gene PIK3CA and breast carcinoma.